Next-generation CAR-T and CAR-NK cell therapies in hematologic malignancies: engineering for persistence, specificity, and safety
Discover Oncology · 27.02.2026 · 17 (1)
DOI: 10.1007/s12672-026-04731-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Discover Oncology, online erschienen am 27.02.2026. Verfasst von Mutaz Jamal Al-Khreisat und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T-cell therapy has profoundly reshaped the therapeutic landscape for hematologic malignancies, achieving remarkable response rates in relapsed/refractory B-cell leukemias and lymphomas. Despite this success, significant challenges persist regarding long-term CAR-T cell persistence, precise tumor specificity, and the management of treatment-related toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Concurrently, CAR-Natural Killer (CAR-NK) cell therapy is emerging as a compelling alternative, offering inherent safety advantages, including a reduced risk of CRS and graft-versus-host disease (GvHD), alongside a promising “off-the-shelf” potential. This review examines the current state of CAR-T and CAR-NK cell therapies in hematologic malignancies, detailing advanced engineering strategies aimed at enhancing their persistence, improving tumor-specific targeting, and bolstering safety. It delves into innovations such as optimized CAR designs, cytokine and metabolic engineering, multi-antigen targeting, and the implementation of sophisticated safety switches. Future directions emphasize the integration of cutting-edge technologies, including advanced gene editing, non-viral delivery systems, and artificial intelligence (AI)-driven CAR design, alongside rational combination therapies, to achieve more durable, precise, and widely accessible treatments for hematologic cancers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
- Department of Pharmacology and Toxicology, College of Pharmacy, Al Farahidi University, Baghdad, Iraq. waleedk.abdulsahib@uoalfarahidi.edu.iq.
- Department of Pharmaceutics, Faculty of Pharmacy, Al-Turath University, Baghdad, Iraq.
- Department of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
- Department of Medical Oncology, IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, 751003, India.
- Department of Biomedical, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Zitieren
APA
Al-Khreisat, M. J., Abdulsahib, W. K., Jasim, I. K., Malathi, H., Nayak, P. P., Anand, D. A., Mukherjee, G., Sinha, A., & Kholboyev, N. (2026). Next-generation CAR-T and CAR-NK cell therapies in hematologic malignancies: engineering for persistence, specificity, and safety. Discover Oncology, 17(1). https://doi.org/10.1007/s12672-026-04731-9
Vancouver
Al-Khreisat MJ, Abdulsahib WK, Jasim IK, Malathi H, Nayak PP, Anand DA, et al. Next-generation CAR-T and CAR-NK cell therapies in hematologic malignancies: engineering for persistence, specificity, and safety. Discover Oncology. 2026;17(1). doi:10.1007/s12672-026-04731-9
BibTeX
@article{AlKhreisat2026,
author = {Al-Khreisat, Mutaz Jamal and Abdulsahib, Waleed K and Jasim, Ihsan Khudhair and Malathi, H and Nayak, Priya Priyadarshini and Anand, D Alex and Mukherjee, Gunjan and Sinha, Aashna and Kholboyev, Norbek},
title = {Next-generation CAR-T and CAR-NK cell therapies in hematologic malignancies: engineering for persistence, specificity, and safety},
journal = {Discover Oncology},
year = {2026},
volume = {17},
number = {1},
doi = {10.1007/s12672-026-04731-9}
}
EUVIMED